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Abstract
Background: Cervical cancer screening programmes have markedly reduced the incidence and
mortality rates of the disease. A substantial amount of deaths from the disease could be prevented
further by organised screening programmes or improving currently running programmes.
Methods/Design: We present here a randomised evaluation trial design integrated to the Finnish
cervical cancer screening programme, in order to evaluate renewal of the programme using
emerging technological alternatives. The main aim of the evaluation is to assess screening
effectiveness, using subsequent cancers as the outcome and screen-detected pre-cancers as
surrogates. For the time being, approximately 863,000 women have been allocated to automation-
assisted cytology, human papillomavirus (HPV) DNA testing, or to conventional cytology within the
organised screening programme. Follow-up results on subsequent cervical cancers will become
available during 2007–2015.
Discussion: Large-scale randomised trials are useful to clarify effectiveness and cost-effectiveness
issues of the most important technological alternatives in the screening programmes for cervical
cancer.
Background
Conventional pap smear screening has reduced effectively
incidence and mortality rates of cervical cancer in several
countries [1-5]. The rates vary still greatly between coun-
tries. Along with the background risk, variation in the
rates depends largely upon availability and also quality of
screening.
During the last decade new screening methods have been
developed. However, validation of the new technological
options has almost entirely relied on intermediate param-
eters, such as screen-detected findings; in many cases only
on the numbers in cytological findings. Those evaluations
interfere with serious limitations, due to large variation in
the rates of screen-detected lesions and also their regres-
sion potentials. Therefore invasive cervical cancers diag-
nosed after screening or prevented by screening has been
proposed as the standard for assessing screening validity
[6]. Along with sensitivity, specificity; or, e.g. test or treat-
ment rates; should be compared with numbers of pre-
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increase, but there prove to be no clearly better impact,
then the new technique is not better than the conven-
tional one. Considering the long duration of pre-cancer-
ous lesions – averaging 10–12 years [6] – this possibility
can be clarified only with rather long-lasting follow-up
studies.
We introduce here a randomised screening design to eval-
uate technological alternatives in cervical cancer screen-
ing. The design and corresponding protocol have been
developed and integrated in the Finnish cervical cancer
screening programme. The design enables early large-scale
implementation, and is aiming by that means to evaluate
the ultimate effectiveness of the screening programmes
with the technological alternatives. We also report the cur-
rent status of this evaluation trial, discuss the most
updated results available thus far on the intermediate
markers, and discuss conditions relevant for comparative
studies in other European countries. The latter aspect is
important when considering possibilities for joint analy-
ses.
Methods and design
Effectiveness conventional screening
In Finland (population 5.2 million; target population 1.2
million, women in ages 30–64 years) a nation-wide effec-
tive programme for cervical cancer screening has been in
action for four decades. Currently the age-adjusted death
rate from cervical cancer is about 1/100,000 woman-years
(national average during 1999–2003, annual world-
standardised rate) – more than 85% lower than the level
before screening [7]. Among the five similarly developed
Nordic countries (overall population 25 million) with
variable screening practices [8] about 1000 deaths are
avoided per year; however, nearly 1500 could be avoided
with optimal screening [9].
In the whole Europe, there are five-fold differences in the
current cervical cancer rates between countries [10,11].
About 60,000 incident cervical cancer cases are diagnosed
annually, and some 30,000 deaths are estimated to take
place from the disease (Figure 1). Some countries lack cer-
vical cancer screening totally whereas an organised
national programme is running only in a minority of the
countries [6,8]. There are no systematic studies available
on screening effectiveness in whole Europe, due to lack of
historical information on screening and in many areas on
cervical cancer.
Alternative screening techniques and information 
available on their sensitivity
Over the years several new technologies have been pro-
posed for screening: automation-assisted cytology [12-
14], liquid-based cytology (LBC) [15,16], and HPV-DNA
testing [17-21]. More recently, HPV-mRNA [22,23] and
tests based on the integration of HPV in the genome or
cell regulation (such as p16INK4A) [6,24] have been pro-
posed as a screening tests, or for triaging or confirmation
of progressive lesions. Vaccination against HPV infections
and cervical neoplasia will become a new option for pre-
vention and will likely affect screening programmes [25-
27].
For a single Pap smear screening test, a false negative
result for any cervical intraepithelial neoplasia (CIN) or
worse varies between 30–70% [28,29]. A proportion of
these lesions regress spontaneously [6,30]. The sensitivity
of the Pap test is quite good to detect lesions that would
progress invasive within few years from testing, sensitivity
among screened is about 80–90% [31].
In an early randomised study, automation-assisted screen-
ing has been reported to have almost a twofold detection
rate of invasive cervical cancer and CIN3 in comparison
with conventional cytology [12]. However, this was not
confirmed in a later study [32], where the detection rate
was similar between the two methods. HPV-DNA test
method has been suggested possibly to be more sensitive
than the Pap smear, but with lower specificity [6]. On
LBC, there are some 60 cross-sectional studies suggesting
similar or higher detection rates [16].
Purpose of the evaluation trial
The cross-sectional validity information available on the
alternative screening techniques interfere with serious
limitations, due, e.g., to regression potentials largely
unrecognised. The purpose of the current randomised
evaluation trial is to evaluate efficacy and effectiveness of
the alternative screening techniques using cancer inci-
dence and mortality follow-up as the gold standard. Along
with sensitivity, also specificity and corresponding test
and treatment rates will be compared between the screen-
ing methods. For the current Finnish study, randomised
evaluations have been chosen to take place for automa-
tion-assisted cytological screening and for primary screen-
ing with an HPV-DNA test.
Ethical and medico-legal aspects
Conventional cytological screening for cervical cancer,
including histological confirmation and colposcopy-
directed treatments, has been proven effective and it is
considered applicable as a public health policy [6,33]. The
structure of the screening programme with invitations,
screening tests, histologically confirmed pre-cancerous
lesions and their management enables introduction of
test modifications or other similar components under safe
conditions. Safety is maintained by cross-sectional or lon-
gitudinal pilot studies preceding a large-scale randomised
evaluation phase, and by monitoring the cross-sectionalPage 2 of 8
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Estimated age-standardised death rates and numbers of deaths from cervical cancers in European regions (Globocan 2002)Figure 1
Estimated age-standardised death rates and numbers of deaths from cervical cancers in European regions (Globocan 2002); a) 
Age-adjusted (ASR(W)) mortality rate from cervical cancer in Europe, and b) Numbers of deaths from cervical cancer in 
Europe.
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tematic monitoring and quality assurance will be done
according to specifically defined protocols for each tech-
nology [6,33]. In a randomised study, this includes defin-
ing stopping rules.
The infrastructures and settings for organised screening as
well as for randomised screening within the organised
programme vary a lot between countries. In Finland, indi-
vidual randomisation has been conducted while drawing
the invitations from population files. There is a continu-
ous linkage between invitation, screening and cancer reg-
istry files, based on the national legal framework for
organised screening and for data collection within health
care. Informing women takes places under the normal
practice within the screening programme. For HPV screen-
ing, further efforts have been done to train sample-taking
nurses within the activity area, including how to commu-
nicate with women; as well as a brief leaflet produced to
be attached with the invitation letter to screening. The
woman has a right to refuse from the HPV-DNA test; in
such as case the conventional smear will be performed.
Written informed consent for registration purpose is not
required. The protocols for the current randomised
screening have been approved by the Ethical Committee
of the National Research and Development Centre for
Welfare and Health (STAKES, 4151/54/98), by the Ethical
Committee of the Obstetrics and Gynaecology in Hospital
District of Helsinki and Uusimaa (221/E8/02), by the
National Authority for Medicolegal Affairs (3950/32/300/
02), and by other health-care authorities [14,21,36].
Informing women, as well as data registration has been
organised in accordance with directive on personal data
registration and corresponding national legislation (95/
46/EC)[34,35].
Protocol in brief
In Finland, women in ages 30 to 60 are invited to the cer-
vical cancer screening programme, in some municipalities
in addition women of ages 25 and/or 65; and in case of a
normal result the invitational interval is 5 years. Referral
to colposcopy and biopsy takes place after clearly positive
cytology (Papanicolaou groups III-V; equivalent to LSIL+
according to the Bethesda 2001 classification) or after
repeated borderline findings (group II, equivalent to ASC-
US) based on the recommendation by the cytologist.
Women will be assigned either to the intervention arm or
to the conventional screening arm within the area of the
participating cytology laboratories when processing the
invitational data to the programme. In automation-
assisted screening, this information will be made availa-
ble through the screening notification cards passed to the
cytology laboratories together with the screening slides.
When indicated, the laboratories scan and analyse the
slides using the automation-assisted method (Papnet),
and also record along with the intention also the method
which was actually used [14,32,36]. Otherwise the screen-
ing process is similar than in the conventional practice.
In the HPV screening arm, the sample-taking nurse col-
lects the conventional cytological sample, and the HPV-
DNA test sample will be produced thereafter from the
endocervical subsample by placing the tip of the sampler
brush of the kit to the transport medium. Primarily, the
HPV-DNA test sample will be analysed in the cytology
laboratory using high-risk HPV Hydrid Capture 2 assay
(Digene Corporation). If the HPV-DNA test is positive
(the relative light unit ratio ≥ 1.00), then the pap smear
will be analysed as a triage for investigating whether the
woman needs directly a referral [20,21]. If the HPV-DNA
test is positive but the cytology negative, the woman will
be re-invited after a year.
Study size estimates
Available estimates on sensitivity error make basis for cal-
culating of statistical power and study size. In Finland, the
absolute rate of invasive cervical cancer after screening
cytologically negative within the programme is 5.2 per
100,000 woman-years [37]. There is no good data on cur-
rent CIN3+ incidence available, but we estimate latter to
be about four-fold to the invasive cancer rate.
The subsequent cancer rate is affected by background risk,
age groups targeted, quality and history of screening, and
follow-up data quality. In the Nordic countries, variation
in the cervical cancer incidence rates in time before screen-
ing was up to two-fold in comparison with the Finnish
ones [38] and one cannot rule out even more variation in
a larger geographical area [10,39]. Somewhat higher dis-
ease rate estimates (10, 15, 20 cases per 100,000) than
reported for the subsequent invasive cervical cancer inci-
dence from the Finnish programme were therefore also
used.
In study size estimates we used a test for differences in
screening effects [40]. We assumed that if the proposed
improvements in screening sensitivity were true, about
50% improvement in screening efficacy could be maxi-
mally obtained, in comparison with conventional screen-
ing, and that 30% or no improvement of sensitivity might
be realistic alternatives as well. Respectively, equivalence
– where the required study size is likely to be larger [41] –
could also be considered depending upon the method.
Calculations presented are valid for any intervention,
including HPV vaccination, among women screened neg-
ative.
The minimum population size, required for a marginal
effect of 50% in further reducing subsequent cervical can-
cer incidence, varies from 0.3 to 1.0 million woman-yearsPage 4 of 8
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power 80%; two-sided). This assumes that attendance rate
is unaffected. There may be drop-outs also due to techni-
cal difficulties, or unwillingness of the invited women to
have the allocated test; which can be considered conse-
quently. Verifying a marginal decrease of 30% necessi-
tates, respectively, about 2 to 3 fold materials (Table 1).
Results
The feasibility phase started in Finland in 1997 and the
first randomised screening activity in 1999 by introducing
the automation-assisted technique. In 2003 primary HPV-
DNA testing for high risk HPV types (with Hybrid Capture
2) was introduced. During 1999–2005 approximately
860,000 women have been randomised (table 2). In areas
with automation-assisted screening the sampling ratio has
been 1:2 (and 1:1:1 in areas with HPV screening included,
from 2003 onwards). First reports on screening detection
rates are available [14,21,32,36]. Screening detection rates
in automation-assisted screening are very similar to con-
ventional screening. Based on very early results (about
5,000 women randomised during 2003) the detection
rate of mild pre-cancerous lesions was in excess in the
HPV screening protocol. The first report on the interval
cancer incidence in automation-assisted screening is
expected during the course of 2006–2007, and final anal-
yses of incidence of invasive cancer and CIN3+ later on
2010–2015, including HPV screening.
After two screening rounds (5–9 follow-up years by birth-
cohort) the statistical power of the Finnish study will be
sufficient to find a rather small (50%) marginal effect in
the invasive cancer incidence (automation-assisted
screening) or CIN3+ incidence (HPV screening) between
the compared technologies.
Discussion
Public health policies are evaluated often at an ecological
level. Randomised settings offer possibilities for optimal
evaluation, however [42]. There are few other examples of
cancer screening programmes with randomisation. In Fin-
land the nationwide breast cancer screening was imple-
mented in 1980s by a randomised design [43], and
randomised implementation of colorectal cancer screen-
ing started in 2004 [44].
Conventional cytological screening, including confirma-
tion and treatment, is considered applicable as a public
health policy based upon evidence available up to inva-
sive cervical cancer endpoints [6,33]. Similar information
is not available for the new methods. The European
Union recommends a programme to use conventional
Pap smears, even though modifications are acceptable.
The recommendation does not guide in detail how de
novo programmes or new techniques should be imple-
mented and evaluated. The IARC work group recom-
mends, on the other hand, that only rather restricted
demonstration projects need to precede large-scale imple-
mentation of new test methods, including HPV-DNA test,
in cervical cancer screening programmes; and that the
large-scale implementation needs to be designed so as to
allow long-term evaluation with randomised designs.
Decisions when or if to implement a new technique have
differed greatly. In many countries, some LBC methods
are already used routinely whereas many other countries
are awaiting for results from RCT-type randomised trials
[45,46]. As to HPV-DNA testing, there are several options
how to integrate the test [45,46]. In primary screening one
need to decide whether to use HPV-DNA test as a sole test,
or as an additional test to cytology.
Unlike cytological test, HPV-DNA test does not indicate
who is in the immediate need of confirmation and treat-
ment. After a positive HPV-DNA test, cytological informa-
tion is still required to find the right person for
colposcopical examination [47]. Sole HPV-DNA test
might lead to many unnecessary colposcopies, because
most of the infections will regress rapidly without causing
significant cellular atypia. Currently, the treatment deci-
Table 1: Study size to obtain 80% statistical power in the proposed screening interventions for different baseline rates for invasive 
cervical cancer incidence assuming various marginal effects, when α = 0.05 and intervention to control ratio 1:1
Invasive cervical cancer incidence per 105 
woman-years1
RR Woman-years in follow-up (intervention 
group); 1-sided test
Woman-years in follow-up (intervention 
group); 2-sided test
5 0.5 820,000 1,020,000
5 0.7 2,467,000 3,097,000
10 0.5 410,000 510,000
10 0.7 1,233,000 1,548,000
15 0.5 273,000 340,000
15 0.7 822,000 1,032,000
20 0.5 205,000 255,000
20 0.7 617,000 774,000
Calculation assumes inclusion of all the ages within organised screening for cervical cancer.
1 In Finland the baseline rate for invasive cervical cancer incidence is approximately 5, in the combined European material from 10 to 20Page 5 of 8
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from colposcopy-directed biopsies and the treatments are
done with aid of the colposcope. Thus pap smears can be
used as a triage after a positive HPV-DNA test to define the
need of colposcopy [20,21]. Under the above conditions
also HPV-DNA testing can be considered as a modifica-
tion to the screening programme and thus it is suitable for
a randomised evaluation trial phase.
In countries presently without any screening, organising
an effective programme is an urgent need. These coun-
tries, many of them in the Eastern Europe, need to con-
sider which technology to use in organising their cervical
cancer screening. Laboratory, training & education, and
other such demands differ a lot between test technologies.
Screening as adopted in the well-to-do health care systems
is not optimal as to their cost-effectiveness and certainly
not for a different or low-resource environment [48]. Tar-
geted screening age groups and intervals, and lifetime
numbers of tests and treatments differ between screening
policy and by technology options, contributing total cost-
effectiveness. Particularly, no good observational infor-
mation exists on how many tests lifetime are required in a
primary HPV screening programme.
Usual time frame required from the start of feasibility
phase up to the final information on the efficacy and
effectiveness of new technology is about twenty to thirty
years. With efficient collaboration and uniform designs
this time can be shortened up to about ten years. The ran-
domised implementation of screening results in more
rapid evidence of new methods and spontaneous imple-
mentation will do.
To conclude, running a randomised evaluation trial
within a screening programme, where the experimental
arm – the exposure – is the public health policy with new
technology and the control arm is the old policy, is a fea-
sible approach for screening programmes for cervical can-
cer. Current information on validity of various competing
screening methods does not directly relate to occurrence
of interval cancers. Potential for improved sensitivity and
effectiveness, but instantaneously also the cost-effective-
ness aspects and potential harm need to be taken into
consideration when considering the public health policies
organised with the technological alternatives.
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